title: Efficient killing effect of osteosarcoma cells by cinobufacini and cisplatin in combination.
abstract: OBJECTIVE
  To study the killing effects on osteosarcoma cells of cinobufacini and cisplatin in combination and the related mechanisms so as to explore the chemotherapeutic method with integrated traditional Chinese and Western medicines.
  
  
  METHODS
  Cinobufacini and cisplatin were applied to OS732 cells singly or jointly and survival rates were measured by MTT assay. Changes in cellular shape were observed with inverted phase contrast and fluorescence microscopy and apoptosis rates were analyzed with flow cytometry (FCM). Immunocytochemistry were used to examine the Fas expression of OS732 cells.
  
  
  RESULTS
  The combination of cinobufacini and cisplatin had the effect of up-regulating Fas expression and inducing apoptosis. The survival rate of combined application of 100 μg/ml cinobufacini and 1 μg/ml cisplatin on OS-732 cells was significantly lower than with either of the agents alone (p<0.01). Changes in cellular shape and apoptotic rates also indicated the apoptosis-inducing effects of combined application were much enhanced.
  
  
  CONCLUSIONS
  The combination of cinobufacini and cisplatin demonstrated strong killing effects on OS-732 cells which might be related to up-regulation of Fas expression.
authors.affiliation: Department of Orthopedics, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China. huangtao@mail.cmu.edu.cn
authors.forename: Tao
authors.initials: T
authors.lastname: Huang
authors.forename: Wei-Hua
authors.initials: WH
authors.lastname: Gong
authors.forename: Xiu-Cheng
authors.initials: XC
authors.lastname: Li
authors.forename: Chun-Ping
authors.initials: CP
authors.lastname: Zou
authors.forename: Guang-Jian
authors.initials: GJ
authors.lastname: Jiang
authors.forename: Xu-Hui
authors.initials: XH
authors.lastname: Li
authors.forename: Hao
authors.initials: H
authors.lastname: Qian
mesh_terms: D000664:Amphibian Venoms / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology*; D006801:Humans; D012516:Osteosarcoma / Q000188:drug therapy* / Q000473:pathology; D015996:Survival Rate; D019014:fas Receptor / Q000096:biosynthesis
chemical_list: D000664:Amphibian Venoms; C491901:FAS protein, human; D019014:fas Receptor; C545813:huachansu; D002945:Cisplatin